HOME >> BIOLOGY >> NEWS
Light to moderate drinking during pregnancy can affect adolescent growth

  • Children with Fetal Alcohol Syndrome (FAS) commonly have growth deficits.
  • Growth deficits also exist among children prenatally exposed to alcohol but without FAS.
  • Researchers have found significant growth deficits among non-FAS children 14 years after birth.
  • The deficits have a dose-response relation to gestational exposure, and are evident at consumption levels less than one drink per day.

Growth deficits are common among children with Fetal Alcohol Syndrome (FAS), affecting their height, weight, and head circumference. Growth deficits have also been found among offspring exposed to alcohol during gestation but who have not developed FAS. Studies have, however, differed in this finding. Furthermore, few studies have followed offspring who were prenatally exposed to alcohol beyond their early and middle childhoods. A study in the October issue of Alcoholism: Clinical & Experimental Research examines the effects of alcohol exposure during gestation on the size of non-FAS offspring at 14 years of age.

"The Maternal Health Practices and Child Development Project began in 1982," said Nancy L. Day, professor of psychiatry and epidemiology at the University of Pittsburgh School of Medicine and lead author of the study. "Its purpose has been to study the effects of prenatal exposure to alcohol, marijuana, tobacco, and other illicit drugs on the growth and development of the offspring. At numerous intervals, we have measured demographic status, the psychological, social, and household environment, maternal and paternal substance use, and substance use of the male partner in the household. We have also assessed the children's cognitive, behavioral, academic, and physical status. Furthermore, at ages 10, 14, and 16, we have additional measures of the children's pubertal maturity, neuropsychological status, cognitive and behavioral development, affect, academic performance, psychiatric status, delinquent behavio
'"/>


15-Oct-2002


Page: 1 2 3 4

Related biology news :

1. Light turns on anticancer agents
2. Light Biology, a biotech company based on UT Southwestern technology, bought by NimbleGen Systems
3. Shedding Light on Disease: A Briefing for Journalists
4. Light at the end of the tunnel: Photonics are tipped to make global communications network a reality
5. Light shed on vision and hearing disorders
6. Brookhaven Spotlights: News from the National Synchrotron Light Source
7. Light receptor may be key in how animals use Earths magnetic field
8. Studies Of A Gene For A Rare Form Of Rickets Shed Light On Vitamin D Deficiencies
9. New Study By TSRI Scientists Sheds Light On Viral Clearance In Acute Hepatitis B Infection
10. Fake Photosynthesis? Test-Tube System In Science Paper Sheds Light On The Oxygen We Breathe, UD Prof Says
11. Sunscreen Ingredient Causes DNA Damage In Light

Post Your Comments:
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: